Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required) | RFA CA 24 025

Opportunity Information: Apply for RFA CA 24 025

The National Cancer Institute (NCI), through the National Institutes of Health (NIH), is soliciting applications for a cooperative agreement to run the Data Management, Auditing, and Statistical Center (DMASC) for the Cancer Prevention Clinical Trials Network (CP-CTNet). This opportunity is designed to strengthen and maintain the core infrastructure needed to carry out early-phase cancer prevention clinical trials, specifically phase 0 through phase 2 studies. CP-CTNet is the Division of Cancer Prevention (DCP) main platform for early clinical development of preventive interventions, meaning it focuses on generating the kind of early human evidence that can justify larger, later-stage prevention trials or other downstream development steps.

The clinical trials supported by this network are aimed at testing cancer prevention interventions across multiple organ sites, with an emphasis on understanding biologic effects in people and identifying clinically meaningful correlates (for example, biomarkers, intermediate endpoints, or other measurable signals that show whether an intervention is affecting cancer-related pathways). The larger purpose is not simply to run trials for their own sake, but to produce high-quality evidence that helps decide which preventive strategies are promising enough to advance further. The network is also expected to support collaboration across studies and across participating sites, so that methods, data, and lessons learned can be harmonized and used efficiently.

This particular Notice of Funding Opportunity (NOFO) focuses on the DMASC, which functions as the operational backbone for the network rather than as a trial site. The DMASC is expected to provide centralized database and data management support for multiple trials, ensure that trial data are collected and handled in a consistent and reliable way, and implement auditing functions that protect data integrity and participant safety. In practice, this typically includes building and maintaining clinical trial databases, establishing data standards and quality control procedures, overseeing data submissions and cleaning, supporting regulatory-compliant data handling, and conducting or coordinating audits to verify that sites follow protocols and that data match source documentation when required. On top of that, the DMASC provides statistical leadership and support, which commonly covers study design input, randomization and sample size planning where relevant, statistical analysis plans, interim and final analyses, and consistent reporting that meets NIH/NCI expectations. The NOFO also describes coordinating functions for the network, reflecting the need for a central hub that can keep multi-site, multi-trial activities aligned on timelines, deliverables, and shared procedures.

The award uses the UG1 cooperative agreement mechanism and is marked as a clinical trial required opportunity. A cooperative agreement is different from a standard grant because NIH/NCI expects substantial programmatic involvement during the project, meaning the awardee works closely with NCI staff on planning, oversight, and execution. The funding opportunity is identified as RFA-CA-24-025, categorized as discretionary, and falls under activity areas of education and health. The CFDA numbers listed are 93.393 and 93.399, which align with NCI assistance programs.

Eligibility is broad and includes many types of U.S.-based organizations and governmental entities. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses); and small businesses. The NOFO also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions. At the same time, it clearly limits foreign participation: non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components are allowed as defined by the NIH Grants Policy Statement, which typically means a U.S. applicant can include certain well-justified foreign elements in the project while keeping the applicant organization and primary infrastructure domestic.

Key timing information included in the source data lists an original closing date of 2024-10-31, and a creation date of 2024-08-12. The award ceiling and expected number of awards are not specified in the provided extract, so applicants would need to consult the full NOFO for budget expectations, project period details, and the anticipated scale of the DMASC effort. Overall, this opportunity is best understood as a call for a capable central center to run the data, quality, auditing, statistical, and coordinating operations that allow CP-CTNet to execute multiple early-phase cancer prevention trials efficiently, credibly, and in close partnership with NCI.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
• This funding opportunity was created on 2024-08-12.
• Applicants must submit their applications by 2024-10-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA CA 24 025

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: